表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % | RMB | 65.96 | | | 茲提述本公司於2025年3月17日 ...

药明康德（603259）(02359)发布公告，该公司于2025年8月12日斥资2799.23万元人民币回购30.79万股 股份，每股回购价格为90.13-91.6元人民币。 ...

格隆汇8月12日丨药明康德(02359.HK)发布公告，2025年8月12日耗资2799.23万元人民币回购30.79万股 A股，回购价格每股90.13-91.6元。 ...

智通财经APP讯，药明康德(02359)发布公告，该公司于2025年8月12日斥资2799.23万元人民币回购30.79 万股股份，每股回购价格为90.13-91.6元人民币。 ...

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

来源：金融界 序号代码名称最新价涨跌幅主力净流入主力净占比1002173创新医疗20.599.992.50亿元7.9%2002622皓宸 医疗3.569.881.12亿元34.67%3301096百诚医药60.512.073461.18万元8.02%4605186健麾信息 23.761.242536.86万元16.7%5002044美年健康5.260.192272.94万元5.8%6300759康龙化成28.96- 0.171772.85万元1.66%7000516国际医学5.450.741482.03万元6.9%8301033迈普医学88.810.38858.71万元 4.1%9301267华厦眼科20.83-0.38853.90万元5.56%10002219新里程2.2-0.9715.88万元5.51% 主力资金净流出居前的分别为药明康德（1.53亿元）、爱尔眼科（1.14亿元）、成都先导（7774.55万 元）、润达医疗（6132.92万元）、昭衍新药（5117.86万元）。 8月12日，医疗服务行业上涨0.07%，今日主力资金流出2.27亿元，成分股17只上涨，25只下跌。 ...

公募基金二季报本周进入密集披露期，部分头部基金及知名基金经理的调仓动向也备受市场关注。 综合来看，各家基金在二季度保持了高仓位运作，新能源产业链、医药消费等成为关注重点。 此外，睿远基金傅鹏博管理的基金则对光伏行业板块个股更为关注。综合季报，通威股份、迈为股 份等新晋十大重仓股，大族激光、先导智能等退出前十大重仓股序列；由傅鹏博、朱璘管理的睿远成长 价值混合基金前十大重仓股为三安光电、中国移动、立讯精密、东方雨虹、万华化学、通威股份、吉利 汽车、沃森生物、迈为股份、国瓷材料。相比一季度，该基金新进持仓了通威股份、吉利汽车、迈为股 份，而先导智能、大族激光、卫宁健康则被调出十大重仓股序列；广发基金刘格菘持仓结构没有出现大 幅调整。其前十大重仓股当中，亿纬锂能、龙佰集团的持仓量不变，国联股份、福莱特分别新晋成为第 七大重仓股和第九大重仓股。另外，晶澳科技、隆基绿能、锦浪科技等多只个股持股数量均较一季度末 有所增长。 Wind数据显示，截至7月20日记者发稿时，已经有多家基金公司旗下1338只股票型开放式基金（未 合并A/C）发布了二季度报告，其中不乏头部基金公司和张坤、刘格菘、傅鹏博、李晓星等知名基金经 理。易方 ...

Group 1 - The insurance institutions and pension accounts have significantly increased their holdings in listed companies, with a total of 3.49 billion shares valued at 12.843 billion yuan as of August 17 [1] - Pension accounts appeared in the top ten shareholders of 33 stocks in the second quarter, with a total holding of 3.26 billion shares valued at 5.392 billion yuan [1] - The largest holding by pension accounts is in Focus Media, with approximately 150 million shares, while Shengtu Mining follows with 28.63 million shares [1] Group 2 - The pension accounts have a significant presence in the pharmaceutical and electronics sectors, with notable holdings in companies like Aiyingshi and Yuhua Tian [2] - The Basic Pension Insurance Fund 16041 combination increased its holdings in Jizhi Technology and Nuohua Zhiyuan by 2.4281 million shares and 1.2976 million shares, respectively [2] - The Basic Pension Insurance Fund 16022 combination also increased its stake in Blue Sky Technology by 4.8997 million shares [2] Group 3 - Approximately 20 companies held by pension accounts reported net profit growth, with Yongxing Materials showing a remarkable increase of 647.64% in net profit [3] - Sunlord Electronics, despite a decline in revenue and net profit, was newly held by the Basic Pension Insurance Fund 802 combination with a holding of 12.5318 million shares valued at 340 million yuan [3] - Lingrui Pharmaceutical saw a new holding of 13.6028 million shares from the Basic Pension Insurance Fund 15022 combination, with a market value of 170 million yuan [3] Group 4 - More than ten insurance institutions entered the top ten shareholders of several listed companies in the second quarter, focusing on manufacturing and energy sectors [4] - Taikang Life's products became top shareholders in companies like Lansi Heavy Industry and Jinqiao Huazhong [4] - Major companies like China Unicom and WuXi AppTec remain favored by institutional investors, with market values of 11.039 billion yuan and 5.510 billion yuan, respectively [4]

Core Insights - The CXO (Contract Research Organization and Contract Development and Manufacturing Organization) sector in A-shares shows a mixed performance in the first half of the year, with 19 out of 35 companies reporting a year-on-year profit increase, indicating a positive trend in the industry [1] Group 1: Company Performance - WuXi AppTec leads the CXO companies with a net profit of 5.313 billion yuan, followed by Kelun Pharmaceutical with 1.686 billion yuan, and Tigermed with 1.388 billion yuan [2] - WuXi AppTec's revenue reached 18.871 billion yuan, a year-on-year increase of 6.28%, with a net profit growth of 14.61% [2] - Kelun Pharmaceutical reported a revenue of 4.622 billion yuan, a decline of 8.33%, and a net profit decrease of 3.09% [3] Group 2: Sector Trends - The demand for peptide drugs, traditional Chinese medicine, and ADC (Antibody-Drug Conjugates) is increasing, leading to significant order growth for some CXO companies [4] - WuXi AppTec's TIDES business, focusing on oligonucleotides and peptides, generated 1.33 billion yuan in revenue, a growth of 37.9%, with a backlog of orders increasing by 188% [4] - The CRO service provider Boji Pharmaceutical reported a 49% increase in new business contracts, with traditional Chinese medicine contracts growing by approximately 400% [4] Group 3: Market Expansion - Despite a cooling investment environment in the global pharmaceutical sector, several CXO companies are experiencing growth in overseas markets [5] - Kelun Pharmaceutical's revenue from U.S. clients reached 3.348 billion yuan, with a 44.77% increase when excluding large orders [5] - Tigermed's revenue was 3.711 billion yuan, a year-on-year increase of 3.25%, with a net profit growth of 16.47% [6]

不到一个半月，药明康德连续抛出了两份10亿元股份回购计划。 3月9日，药明康德启动了第二轮10亿元股份回购计划，继前次于2月5日完成10亿元A股股份回购后，为 进一步维护公司价值和股东权益，公司拟继续通过上海证券交易所系统以集中竞价交易方式回购A股股 票，拟回购资金总额为10亿元，回购完成之后全部予以注销并减少注册资本。 本次回购股份价格不超过83.33元/股（含），回购价格较3月8日收盘价高出60.74%。按回购价格上限 83.33元/股（含）测算，预计本次回购股份数量约为1200.05万股。 萨摩耶云科技集团首席经济学家郑磊向《证券日报》记者表示："回购是提升上市公司股票价值的主要 举措之一，尤其是上市公司将回购的股票注销，直接提高了每股含金量和每股潜在收益水平，同时也给 投资者一个信号，即公司当前股价低于其内在价值，未来可能仍有上升空间。" 药明康德在公告中提到，鉴于截至2024年3月1日公司A股股票连续20个交易日内股票收盘价格跌幅累计 达到20%。3月8日，公司召开第三届董事会第十次会议审议通过《关于以集中竞价交易方式回购公司A 股股份的议案》，同意实施本次回购股份方案。 公司股价不振，从消息面上来 ...